Pfizer, Astellas revise Lipitor development and marketing agreement

Pfizer Japan and Astellas Pharma have agreed to partly revise the development and marketing agreement for Lipitor, a hypercholesterolemia treatment (HMG-CoA reductase inhibitor).

As per the agreement, the term of the development and marketing agreement has been extended from July 2016 to March 2021 and certain financial terms, such as co-promotion fee rate from December 2011 to November 2013, have been revised.

Astellas will pay an upfront payment of JPY1bn to Pfizer.

Lipitor is currently manufactured and distributed by Astellas and promoted jointly by Pfizer and Astellas in Japan.